Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Stifel Virtual Healthcare Conference Transcript

Nov 16, 2020 / 07:00PM GMT
Release Date Price: $131.05 (-3.29%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Awesome. Great. Thanks very much everybody, and thanks for everyone who's been tuning in all day. Happy to be here with the CEO of Alnylam, John Maraganore, from your apartment in Boston. Is that what we're looking at right now?

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

We're in Boston in my apartment. That's right. You got it.

Paul Andrew Matteis;John M. Maraganore
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst;Alnylam Pharmaceuticals, Inc. - CEO &

All right. Awesome. Well, thanks so much for joining, John. I really appreciate it as always.

Everyone knows Alnylam well, but do you want to just kind of set the stage and maybe just quickly recap your recent quarter, program updates and then we can get into specifics?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot